BMC Infectious Diseases:预测治疗中HIV患者的死亡率时病毒载量优于CD4细胞计数

2019-02-24 不详 MedSci原创

目前,CD4细胞计数已被确定为监测HIV治疗结果的重要指标。然而,CD4细胞计数监测有时无法预测病毒学治疗的效果。本研究旨在评估病毒载量(HIV RNA)和CD4细胞计数在监测HIV / AIDS进展中何种更有预测价值。

背景
目前,CD4细胞计数已被确定为监测HIV治疗结果的重要指标。然而,CD4细胞计数监测有时无法预测病毒学治疗的效果。本研究旨在评估病毒载量(HIV RNA)和CD4细胞计数在监测HIV / AIDS进展中何种更有预测价值。

方法
研究人员采用拟合时间齐次马尔可夫模型,一个用于CD4细胞计数监测,另一个用于HIV RNA监测。根据协变量的影响, 评估每种拟合模型的性别,年龄,CD4基线,HIV RNA基线和对治疗的依从性。使用普遍性图和似然比测试来评估拟合模型。

结果
分析结果表明,病毒载量监测可以比CD4细胞计数监测更好地预测HIV / AIDS患者的死亡率。对拟合模型的评估表明,病毒载量监测是比CD4细胞计数更好的HIV / AIDS进展预测因子。

结论
病毒载量监测和CD4计数监测都可用于提供HIV病毒学治疗,这些信息都可用于改善HIV患者的预期寿命。然而,病毒载量监测是比CD4细胞计数更好的HIV / AIDS进展预测因子。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2003366, encodeId=76ec2003366ee, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Sat Nov 02 05:55:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974900, encodeId=e8da19e490041, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Jun 18 12:55:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068343, encodeId=63b92068343f4, content=<a href='/topic/show?id=d411434487' target=_blank style='color:#2F92EE;'>#CD4细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4344, encryptionId=d411434487, topicName=CD4细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Sat Nov 30 23:55:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012955, encodeId=584820129550d, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Feb 25 00:55:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864251, encodeId=4bee186425178, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat Nov 02 13:55:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491149, encodeId=516a14911495f, content=<a href='/topic/show?id=fb94e0991b3' target=_blank style='color:#2F92EE;'>#病毒载量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70991, encryptionId=fb94e0991b3, topicName=病毒载量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c1e8876950, createdName=grace5703, createdTime=Tue Feb 26 05:55:00 CST 2019, time=2019-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541710, encodeId=e6a31541e1021, content=<a href='/topic/show?id=d6e6599e27' target=_blank style='color:#2F92EE;'>#Diseases#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5997, encryptionId=d6e6599e27, topicName=Diseases)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474713318057, createdName=Tamikia, createdTime=Tue Feb 26 05:55:00 CST 2019, time=2019-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569754, encodeId=c4091569e547a, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Tue Feb 26 05:55:00 CST 2019, time=2019-02-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2003366, encodeId=76ec2003366ee, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Sat Nov 02 05:55:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974900, encodeId=e8da19e490041, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Jun 18 12:55:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068343, encodeId=63b92068343f4, content=<a href='/topic/show?id=d411434487' target=_blank style='color:#2F92EE;'>#CD4细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4344, encryptionId=d411434487, topicName=CD4细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Sat Nov 30 23:55:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012955, encodeId=584820129550d, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Feb 25 00:55:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864251, encodeId=4bee186425178, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat Nov 02 13:55:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491149, encodeId=516a14911495f, content=<a href='/topic/show?id=fb94e0991b3' target=_blank style='color:#2F92EE;'>#病毒载量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70991, encryptionId=fb94e0991b3, topicName=病毒载量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c1e8876950, createdName=grace5703, createdTime=Tue Feb 26 05:55:00 CST 2019, time=2019-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541710, encodeId=e6a31541e1021, content=<a href='/topic/show?id=d6e6599e27' target=_blank style='color:#2F92EE;'>#Diseases#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5997, encryptionId=d6e6599e27, topicName=Diseases)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474713318057, createdName=Tamikia, createdTime=Tue Feb 26 05:55:00 CST 2019, time=2019-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569754, encodeId=c4091569e547a, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Tue Feb 26 05:55:00 CST 2019, time=2019-02-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2003366, encodeId=76ec2003366ee, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Sat Nov 02 05:55:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974900, encodeId=e8da19e490041, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Jun 18 12:55:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068343, encodeId=63b92068343f4, content=<a href='/topic/show?id=d411434487' target=_blank style='color:#2F92EE;'>#CD4细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4344, encryptionId=d411434487, topicName=CD4细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Sat Nov 30 23:55:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012955, encodeId=584820129550d, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Feb 25 00:55:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864251, encodeId=4bee186425178, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat Nov 02 13:55:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491149, encodeId=516a14911495f, content=<a href='/topic/show?id=fb94e0991b3' target=_blank style='color:#2F92EE;'>#病毒载量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70991, encryptionId=fb94e0991b3, topicName=病毒载量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c1e8876950, createdName=grace5703, createdTime=Tue Feb 26 05:55:00 CST 2019, time=2019-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541710, encodeId=e6a31541e1021, content=<a href='/topic/show?id=d6e6599e27' target=_blank style='color:#2F92EE;'>#Diseases#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5997, encryptionId=d6e6599e27, topicName=Diseases)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474713318057, createdName=Tamikia, createdTime=Tue Feb 26 05:55:00 CST 2019, time=2019-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569754, encodeId=c4091569e547a, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Tue Feb 26 05:55:00 CST 2019, time=2019-02-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2003366, encodeId=76ec2003366ee, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Sat Nov 02 05:55:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974900, encodeId=e8da19e490041, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Jun 18 12:55:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068343, encodeId=63b92068343f4, content=<a href='/topic/show?id=d411434487' target=_blank style='color:#2F92EE;'>#CD4细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4344, encryptionId=d411434487, topicName=CD4细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Sat Nov 30 23:55:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012955, encodeId=584820129550d, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Feb 25 00:55:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864251, encodeId=4bee186425178, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat Nov 02 13:55:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491149, encodeId=516a14911495f, content=<a href='/topic/show?id=fb94e0991b3' target=_blank style='color:#2F92EE;'>#病毒载量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70991, encryptionId=fb94e0991b3, topicName=病毒载量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c1e8876950, createdName=grace5703, createdTime=Tue Feb 26 05:55:00 CST 2019, time=2019-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541710, encodeId=e6a31541e1021, content=<a href='/topic/show?id=d6e6599e27' target=_blank style='color:#2F92EE;'>#Diseases#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5997, encryptionId=d6e6599e27, topicName=Diseases)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474713318057, createdName=Tamikia, createdTime=Tue Feb 26 05:55:00 CST 2019, time=2019-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569754, encodeId=c4091569e547a, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Tue Feb 26 05:55:00 CST 2019, time=2019-02-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2003366, encodeId=76ec2003366ee, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Sat Nov 02 05:55:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974900, encodeId=e8da19e490041, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Jun 18 12:55:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068343, encodeId=63b92068343f4, content=<a href='/topic/show?id=d411434487' target=_blank style='color:#2F92EE;'>#CD4细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4344, encryptionId=d411434487, topicName=CD4细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Sat Nov 30 23:55:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012955, encodeId=584820129550d, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Feb 25 00:55:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864251, encodeId=4bee186425178, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat Nov 02 13:55:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491149, encodeId=516a14911495f, content=<a href='/topic/show?id=fb94e0991b3' target=_blank style='color:#2F92EE;'>#病毒载量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70991, encryptionId=fb94e0991b3, topicName=病毒载量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c1e8876950, createdName=grace5703, createdTime=Tue Feb 26 05:55:00 CST 2019, time=2019-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541710, encodeId=e6a31541e1021, content=<a href='/topic/show?id=d6e6599e27' target=_blank style='color:#2F92EE;'>#Diseases#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5997, encryptionId=d6e6599e27, topicName=Diseases)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474713318057, createdName=Tamikia, createdTime=Tue Feb 26 05:55:00 CST 2019, time=2019-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569754, encodeId=c4091569e547a, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Tue Feb 26 05:55:00 CST 2019, time=2019-02-26, status=1, ipAttribution=)]
    2019-11-02 qidongfanjian
  6. [GetPortalCommentsPageByObjectIdResponse(id=2003366, encodeId=76ec2003366ee, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Sat Nov 02 05:55:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974900, encodeId=e8da19e490041, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Jun 18 12:55:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068343, encodeId=63b92068343f4, content=<a href='/topic/show?id=d411434487' target=_blank style='color:#2F92EE;'>#CD4细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4344, encryptionId=d411434487, topicName=CD4细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Sat Nov 30 23:55:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012955, encodeId=584820129550d, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Feb 25 00:55:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864251, encodeId=4bee186425178, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat Nov 02 13:55:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491149, encodeId=516a14911495f, content=<a href='/topic/show?id=fb94e0991b3' target=_blank style='color:#2F92EE;'>#病毒载量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70991, encryptionId=fb94e0991b3, topicName=病毒载量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c1e8876950, createdName=grace5703, createdTime=Tue Feb 26 05:55:00 CST 2019, time=2019-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541710, encodeId=e6a31541e1021, content=<a href='/topic/show?id=d6e6599e27' target=_blank style='color:#2F92EE;'>#Diseases#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5997, encryptionId=d6e6599e27, topicName=Diseases)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474713318057, createdName=Tamikia, createdTime=Tue Feb 26 05:55:00 CST 2019, time=2019-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569754, encodeId=c4091569e547a, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Tue Feb 26 05:55:00 CST 2019, time=2019-02-26, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2003366, encodeId=76ec2003366ee, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Sat Nov 02 05:55:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974900, encodeId=e8da19e490041, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Jun 18 12:55:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068343, encodeId=63b92068343f4, content=<a href='/topic/show?id=d411434487' target=_blank style='color:#2F92EE;'>#CD4细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4344, encryptionId=d411434487, topicName=CD4细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Sat Nov 30 23:55:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012955, encodeId=584820129550d, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Feb 25 00:55:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864251, encodeId=4bee186425178, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat Nov 02 13:55:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491149, encodeId=516a14911495f, content=<a href='/topic/show?id=fb94e0991b3' target=_blank style='color:#2F92EE;'>#病毒载量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70991, encryptionId=fb94e0991b3, topicName=病毒载量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c1e8876950, createdName=grace5703, createdTime=Tue Feb 26 05:55:00 CST 2019, time=2019-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541710, encodeId=e6a31541e1021, content=<a href='/topic/show?id=d6e6599e27' target=_blank style='color:#2F92EE;'>#Diseases#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5997, encryptionId=d6e6599e27, topicName=Diseases)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474713318057, createdName=Tamikia, createdTime=Tue Feb 26 05:55:00 CST 2019, time=2019-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569754, encodeId=c4091569e547a, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Tue Feb 26 05:55:00 CST 2019, time=2019-02-26, status=1, ipAttribution=)]
    2019-02-26 Tamikia
  8. [GetPortalCommentsPageByObjectIdResponse(id=2003366, encodeId=76ec2003366ee, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Sat Nov 02 05:55:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974900, encodeId=e8da19e490041, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Jun 18 12:55:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068343, encodeId=63b92068343f4, content=<a href='/topic/show?id=d411434487' target=_blank style='color:#2F92EE;'>#CD4细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4344, encryptionId=d411434487, topicName=CD4细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Sat Nov 30 23:55:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012955, encodeId=584820129550d, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Feb 25 00:55:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864251, encodeId=4bee186425178, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat Nov 02 13:55:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491149, encodeId=516a14911495f, content=<a href='/topic/show?id=fb94e0991b3' target=_blank style='color:#2F92EE;'>#病毒载量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70991, encryptionId=fb94e0991b3, topicName=病毒载量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c1e8876950, createdName=grace5703, createdTime=Tue Feb 26 05:55:00 CST 2019, time=2019-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541710, encodeId=e6a31541e1021, content=<a href='/topic/show?id=d6e6599e27' target=_blank style='color:#2F92EE;'>#Diseases#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5997, encryptionId=d6e6599e27, topicName=Diseases)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474713318057, createdName=Tamikia, createdTime=Tue Feb 26 05:55:00 CST 2019, time=2019-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569754, encodeId=c4091569e547a, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Tue Feb 26 05:55:00 CST 2019, time=2019-02-26, status=1, ipAttribution=)]
    2019-02-26 dongjia2015

相关资讯

Blood:树突细胞不能正常激活CD4 T细胞时可导致骨髓增生

中心点:骨髓增生可能是DC-CD4 T细胞相互作用缺陷以及DCs数目缺陷的结果。摘要:树突细胞(DCs)是适应性免疫应答起始的关键细胞。近期,有研究提示DCs具有抑制骨髓增殖的作用。在构成性敲除DCs的小鼠研究和由GATA2或IRF8突变引起DCs先天性缺陷的患者中均可观察到骨髓增生性疾病(MPD)。DC缺陷和MPD之间的机制关联尚不明确。目前流行的模型表明数目性树突细胞缺陷通过代偿性髓系分化导致

Blood:霍奇金淋巴瘤肿瘤微环境中,CD4+效应T细胞耗竭、调节T细胞富集

中心点:新确诊的原发性cHLs伴随CD4+Th1极化调节T细胞和分化的效应T细胞增多。原发性cHLs表现出两种主要的免疫抑制互补——PD-1+Th1效应细胞耗竭和PD-1-Th1调节T细胞活化。摘要:经典型霍奇金淋巴瘤(cHL)患者抗肿瘤免疫反应失效。霍奇金RS(HRS)细胞有多种逃脱免疫细胞的机制,包括9p24.1/CD274(PD-L1)/PDCD1LG2(PD-L2)遗传变异、PD-1配体过

Lancet HIV:CD4计数与HIV抗逆转录病毒药物治疗收益

研究发现,对于无症状的,未接受过抗病毒治疗的,CD4计数超过500的HIV感染者,若患者年龄超过50岁,CD4/CD8低以及HIV病毒当量较高时,这部分患者进行立即的抗病毒治疗受益显著,应当考虑优先治疗

Blood:重度联合型免疫缺陷患者进行造血细胞移植后6个月,CD4+细胞计数即可预测存活率和免疫重建

原发性免疫缺陷治疗协会对1982-2012年期间采用造血干细胞移植(HCT)作为一线疗法的662位重度联合型免疫缺陷(SCID)患者进行回顾性分析。采用匹配的兄弟姐妹(MSD)的造血细胞移植后,患者的总体存活率升高。对于采用非MSD的HCT的患者,多变量分析显示SCID表型明显影响其存活率和免疫重构。RAG、IL2RG或JAK3缺陷患者的总体存活率相近,均明显高于携带ADA或DCLRE1C突变的患

NEJM:Ibalizumab用于多药耐药性HIV感染者效果显著

研究认为ibalizumab可有效治疗多药耐药性HIV感染

Sci Transl Med:突破!HIV竟是这样逃过免疫检查

近日,加利福尼亚大学旧金山分校的科学家揭示了HIV隐藏在受感染细胞中的新机制,这种机制使HIV处于潜伏状态,可以逃避机体免疫系统并阻止抗病毒药物冲洗出体外。 这项发现于2018年2月28日在Science Translational Medicine杂志上发表,这可能有助于设计和测试旨在治愈病毒的新疗法。